|
|
 |
|
Viewing report
|
|
|
|
US FDA Approval of Afinitor Ends a Three Decade Long Wait for Pancreatic Neuroendocrine Tumor (PNET) Patients
GlobalData, May 2011, Pages: 5
US FDA Approval of Afinitor Ends a Three Decade Long Wait for Pancreatic Neuroendocrine Tumor (PNET) Patients
Summary
On May 5, 2011, the US Food and Drug Association (FDA) approved Afinitor (everolimus) for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. It has become the first drug to be approved for the indication in nearly 30 years. The approval has been particularly important as there are no therapies currently available that can significantly delay tumor growth and improve the progressionfree survival of patients with advanced PNET, and as a result this drug has been eagerly anticipated.
Scope
- Afinitor targets mammalian target of rapamycin (mTOR), and inhibits the action of this serine protein kinase that stimulates cell growth and proliferation leading to reduced tumor cell growth, decreased tumor angiogenesis, thus, inhibition of cell metabolism. Pancreatic NETs generally proliferate by the autocrine activation of the mTOR signaling pathway, mediated through insulin-like growth factor. Consistent with this observation is the finding that inhibition of mTOR has a significant antiproliferative effect on pancreatic neuroendocrine tumor cell lines.
Reasons to buy
- Gives Impact analysis of approval of Afinitor for Pancreatic Neuroendocrine Tumor (PNET) Patients
|
|
|
|
